MCID: PNC016
MIFTS: 37

Pancreatic Cholera

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cholera

MalaCards integrated aliases for Pancreatic Cholera:

Name: Pancreatic Cholera 12 15 73
Excessive Vasoactive Intestinal Peptide Secretion 12
Pancreatic Wdha Syndrome 12
Verner-Morrison Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6977
MeSH 44 D003969
NCIt 50 C3488
SNOMED-CT 68 39998009 70091000
UMLS 73 C0086768

Summaries for Pancreatic Cholera

MalaCards based summary : Pancreatic Cholera, also known as excessive vasoactive intestinal peptide secretion, is related to wdha syndrome and vipoma. An important gene associated with Pancreatic Cholera is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Levoleucovorin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, small intestine and lung, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Wikipedia : 76 A VIPoma or vipoma (/vɪ�?po�?m�?/) is a rare endocrine tumor that overproduces vasoactive intestinal... more...

Related Diseases for Pancreatic Cholera

Diseases related to Pancreatic Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 wdha syndrome 33.5 CALCA SST VIP
2 vipoma 32.9 GAST SCT SST VIP
3 diarrhea 30.4 CCK GAST SST
4 multiple endocrine neoplasia, type i 29.4 GAST GHRH MEN1 SCT SST VIP
5 cholera 10.6
6 large cell carcinoma 10.4
7 pancreatic gastrinoma 10.3 MEN1 SCT
8 angiodysplasia 10.2 SCT SST
9 leprosy 2 10.2 CALCA VIP
10 intestinal neuroendocrine benign tumor 10.2 MEN1 SCT
11 small intestine neuroendocrine neoplasm 10.2 MEN1 SCT
12 hormone producing pituitary cancer 10.2 MEN1 SST
13 binswanger's disease 10.2 SST VIP
14 carcinoid tumors, intestinal 10.2 MEN1 SST
15 cryptosporidiosis 10.2 SST VIP
16 vasomotor rhinitis 10.2 CALCA VIP
17 cluster headache 10.2 CALCA VIP
18 prolactin producing pituitary tumor 10.2 CALCA SST
19 functioning pituitary adenoma 10.2 MEN1 SST
20 duodenum cancer 10.2 MEN1 SST
21 biliary dyskinesia 10.2 CCK SCT
22 diffuse pulmonary fibrosis 10.2 CALCA VIP
23 ectopic cushing syndrome 10.2 MEN1 SST
24 hypophosphatasia, adult 10.2 CALCA SPTA1
25 multiple endocrine neoplasia, type iib 10.2 CALCA MEN1
26 hyperpituitarism 10.2 GHRH SST
27 pancreatic steatorrhea 10.2 CCK SCT
28 malignant pheochromocytoma 10.2 CALCA SST
29 pylorospasm 10.2 GAST SST
30 somatostatinoma 10.2 CALCA SST VIP
31 gastrointestinal neuroendocrine benign tumor 10.2 GAST SST
32 tsh producing pituitary tumor 10.2 GHRH SST
33 gastric neuroendocrine neoplasm 10.2 GAST SST
34 small intestine cancer 10.2 MEN1 SCT SST
35 postgastrectomy syndrome 10.2 GIP SST VIP
36 pernicious anemia 10.1 GAST SST
37 diphyllobothriasis 10.1 GAST SCT
38 metaphyseal chondrodysplasia, jansen type 10.1 CALCA SCT
39 endocrine organ benign neoplasm 10.1 CALCA MEN1 SST
40 familial isolated hyperparathyroidism 10.1 GAST MEN1
41 exocrine pancreatic insufficiency 10.1 CCK SCT
42 steatorrhea 10.1 CCK SCT SST
43 peliosis hepatis 10.1 GHRH MEN1
44 alcoholic pancreatitis 10.1 CCK SCT
45 functional gastric disease 10.1 CCK HRH2 SST
46 thyroid cancer, nonmedullary, 2 10.1 CALCA MEN1 SST
47 dyspepsia 10.1 CCK HRH2 SST
48 acute pancreatitis 10.1 CCK SCT SST
49 pancreatitis 10.1 CCK SCT SST
50 endocrine pancreas disease 10.1 GIP SST

Graphical network of the top 20 diseases related to Pancreatic Cholera:



Diseases related to Pancreatic Cholera

Symptoms & Phenotypes for Pancreatic Cholera

MGI Mouse Phenotypes related to Pancreatic Cholera:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 GAST GIP HRH2 MEN1 SPTA1 SST
2 homeostasis/metabolism MP:0005376 9.28 CCK GAST GHRH GIP HRH2 MEN1

Drugs & Therapeutics for Pancreatic Cholera

Drugs for Pancreatic Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Vitamin B9 Phase 2, Phase 3
11 Immunologic Factors Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3
13 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
14 Folate Phase 2, Phase 3
15 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
16 Antimetabolites Phase 2, Phase 3,Phase 1
17 Liver Extracts Phase 3,Phase 2,Phase 1
18 Cola Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Anesthetics, Intravenous Phase 3
22 Analgesics, Opioid Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Anesthetics, General Phase 3
25 Analgesics Phase 3
26 Narcotics Phase 3
27 Anesthetics Phase 3
28
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
32
Pancrelipase Approved, Investigational Phase 2 53608-75-6
33
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
34
Melphalan Approved Phase 2 148-82-3 4053 460612
35
Somatostatin Approved, Investigational Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
36
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
37
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
38 Vitamin B Complex Phase 2
39 Nicotinic Acids Phase 2
40 Vitamins Phase 2
41 Trace Elements Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Vitamin B3 Phase 2
44 Micronutrients Phase 2
45 Calcium, Dietary Phase 2,Phase 1
46 Antidotes Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
48 pancreatin Phase 2
49 Protective Agents Phase 2,Phase 1
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
4 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
5 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
7 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
8 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
9 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
10 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
11 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
12 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
13 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
14 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
15 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
16 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376

Search NIH Clinical Center for Pancreatic Cholera

Genetic Tests for Pancreatic Cholera

Anatomical Context for Pancreatic Cholera

MalaCards organs/tissues related to Pancreatic Cholera:

41
Pancreas, Small Intestine, Lung, Pituitary, Thyroid

Publications for Pancreatic Cholera

Articles related to Pancreatic Cholera:

(show all 32)
# Title Authors Year
1
Surgical treatment of pancreatic cholera: a case report. ( 8769928 )
1996
2
Increased tear secretion in pancreatic cholera: a newly recognized symptom in an experiment of nature. ( 2845780 )
1988
3
Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. ( 2828145 )
1988
4
Treatment of pancreatic cholera. ( 2827972 )
1988
5
Multiple endocrine neoplasia, type 1, with pancreatic cholera. ( 2886044 )
1987
6
Secretin, cholecystokinin, and vasoactive intestinal polypeptide in pancreatic cholera. ( 3019205 )
1986
7
Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. ( 2856888 )
1985
8
Successful treatment of therapy-resistant pancreatic cholera with human leucocyte interferon. ( 2857998 )
1985
9
Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. ( 2862821 )
1985
10
Pancreatic cholera. ( 6322070 )
1984
11
VIP and the pancreatic cholera syndrome. ( 6325912 )
1984
12
Pancreatic cholera: is the diarrhea due to VIP? ( 6316137 )
1983
13
Streptozotocin treatment in pancreatic cholera (Verner-Morrison) syndrome. ( 6292031 )
1982
14
Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. ( 6122550 )
1982
15
Beneficial effect of oral lithium carbonate in the treatment of pancreatic cholera syndrome. ( 6246427 )
1980
16
Lithium carbonate in pancreatic cholera. ( 7421906 )
1980
17
Trifluoperazine reversal of secretory diarrhea in pancreatic cholera. ( 6250437 )
1980
18
The pancreatic cholera syndrome. ( 6244130 )
1980
19
Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. ( 208414 )
1978
20
Indomethacin-responsive pancreatic cholera. ( 197410 )
1977
21
Intractable diarrhea. Intestinal perfusion studies and plasma VIP concentrations in patients with pancreatic cholera syndrome and surreptitious ingestion of laxatives and diuretics. ( 857657 )
1977
22
Pancreatic cholera. ( 173092 )
1975
23
Letter: Treatment of "pancreatic cholera". ( 166314 )
1975
24
Pancreatic cholera. Sudies on tumoral secretions and pathophysiology of diarrhea. ( 1097288 )
1975
25
Editorial: Streptozotocin for pancreatic cholera.'. ( 49526 )
1975
26
Islet cell carcinoma, pancreatic cholera, and vasoactive intestinal peptide. ( 173221 )
1975
27
Letter: Pancreatic cholera and vip. ( 1160944 )
1975
28
Pancreatic cholera (W.D.H.A. syndrome). Histochemical and ultrastructural studies. ( 170729 )
1975
29
Pancreatic cholera: benefical effects of treatment with streptozotocin. ( 163965 )
1975
30
Pancreatic cholera due to production of gastric inhibitory polypeptide. ( 4116232 )
1972
31
Watery diarrhea, hypokalemia and achlorhydria associated with pancreatic cholera. Case report. ( 4344758 )
1972
32
Two cases of "pancreatic cholera" with features of peptide-secreting adenomatosis of the pancreas. ( 4316433 )
1970

Variations for Pancreatic Cholera

Expression for Pancreatic Cholera

Search GEO for disease gene expression data for Pancreatic Cholera.

Pathways for Pancreatic Cholera

Pathways related to Pancreatic Cholera according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 CALCA CCK GAST GCG GHRH GIP
2
Show member pathways
13.18 CALCA CCK GCG GHRH GIP HRH2
3
Show member pathways
12.12 CALCA GCG GHRH GIP SCT
4
Show member pathways
11.8 GAST HRH2 SST
5 11.33 CALCA GCG GHRH GIP HRH2 SCT
6 10.1 CCK GAST SCT VIP
7 10.07 GAST HRH2

GO Terms for Pancreatic Cholera

Cellular components related to Pancreatic Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.62 CALCA CCK GIP SST
2 extracellular space GO:0005615 9.61 CALCA CCK GAST GCG GHRH GIP
3 perikaryon GO:0043204 9.43 CCK GHRH VIP
4 extracellular region GO:0005576 9.36 CALCA CCK GAST GCG GHRH GIP
5 terminal bouton GO:0043195 9.33 CALCA CCK GHRH

Biological processes related to Pancreatic Cholera according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.7 CALCA CCK GAST GCG GHRH GIP
2 response to amino acid GO:0043200 9.52 GIP SST
3 feeding behavior GO:0007631 9.51 CALCA GCG
4 memory GO:0007613 9.5 CCK GIP HRH2
5 regulation of sensory perception of pain GO:0051930 9.49 CCK VIP
6 digestion GO:0007586 9.48 CCK SST
7 positive regulation of blood vessel diameter GO:0097755 9.46 CALCA VIP
8 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.46 CALCA GCG GHRH VIP
9 response to food GO:0032094 9.43 GAST GHRH
10 positive regulation of protein binding GO:0032092 9.43 GCG MEN1 SPTA1
11 positive regulation of cAMP-mediated signaling GO:0043950 9.4 GIP SCT
12 response to acidic pH GO:0010447 9.37 GIP SST
13 regulation of signaling receptor activity GO:0010469 9.32 CALCA CCK GAST GCG GHRH GIP

Molecular functions related to Pancreatic Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 9.33 CCK GHRH VIP
2 hormone activity GO:0005179 9.32 CALCA CCK GAST GCG GHRH GIP
3 neuropeptide hormone activity GO:0005184 9.26 CCK GHRH PPY VIP

Sources for Pancreatic Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....